DNLI Denali Therapeutics
- 20.510
- +0.270+1.33%
Denali Therapeutics News
Stifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)
Optimistic Outlook for Denali Therapeutics: Buy Rating Affirmed Amidst Positive ERT Developments and Strong Pipeline Progress
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Denali Therapeutics Analyst Ratings
Stifel Maintains Hold on Denali Therapeutics, Lowers Price Target to $22
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Denali Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and ArGEN X (GB:0QW0)
Denali Therapeutics (DNLI) Gets a Buy From Oppenheimer
Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution
Denali Therapeutics Analyst Ratings
Buy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash Runway
Denali Therapeutics: Strong Buy Rating Backed by Financial Fortitude and Strategic Pipeline Advancements
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Denali Therapeutics Analyst Ratings
Buy Rating on Denali Therapeutics: Anticipating Accelerated FDA Approval With CSF HS Biomarker Breakthrough
Analysis
Price Target
No Data
